Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Core Insights - Vigil Neuroscience announced positive Phase 1 clinical trial data for VG-3927, a potential treatment for Alzheimer's Disease, and plans to initiate a Phase 2 trial in Q3 2025 [1][2] - The company is on track to report final analysis from the IGNITE Phase 2 clinical trial for iluzanebart in ALSP in Q2 2025 [1][2] Recent Developments - Positive Phase 1 data for VG-3927 supports its advancement as a Phase 2-ready oral small molecule TREM2 agonist, potentially offering a new therapy for Alzheimer's disease [2][4] - The IGNITE Phase 2 trial for iluzanebart is expected to provide critical data for a potential breakthrough therapy for ALSP [2][4] Financial Performance - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $97.8 million, down from$111.3 million as of September 30, 2024 [8][13] - Research and Development (R&D) expenses for Q4 2024 were $18.7 million, compared to$16.8 million in Q4 2023, driven by increased clinical activity [8][11] - General and Administrative (G&A) expenses decreased to $6.4 million in Q4 2024 from$7.1 million in Q4 2023, attributed to lower external professional service fees [8][11] Clinical Trial Details - The Phase 1 trial for VG-3927 included 115 participants, demonstrating a favorable safety profile and a robust dose-dependent reduction of sTREM2 in cerebral spinal fluid [4][8] - The company plans to present Phase 1 data at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Disease in April 2025 [4][8]